LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics, Inc. following the announcement of adverse reactions in a clinical study, which led to a significant drop in the company's stock price [1][2]. Summary by Sections Investigation Details - The investigation centers on whether Larimar Therapeutics made false or misleading statements or failed to disclose critical information to investors [2]. - On September 29, 2025, Larimar reported data from an ongoing study of Nomlabofusp for Friedreich's Ataxia, claiming positive results while also revealing that seven participants experienced severe allergic reactions or anaphylaxis [2]. Market Reaction - Following the announcement of the study results and the adverse reactions, Larimar's shares fell by over 33.6% on the same day [2].